Advertisement

Organisation › Details
MIG Capital AG
MIG Capital is one of the leading German VC investors. MIG invests in young deep tech and life sciences companies in German-speaking Europe and beyond. The company has so far invested over €680 million in about 50 companies. MIG's portfolio companies develop innovations in areas such as biopharmaceuticals, energy and environmental technologies, advanced computing, digitization / IoT, medical technology and digital health. The MIG investment portfolio currently comprises 30 companies. MIG’s investment team consists of a committed group of experts of engineers, biologists, scientists and investors who use analytical and creative processes to evaluate the risks and opportunities of business models and technologies. Their reputation, experience and network provide excellent access to companies, institutions and decision-makers in order to support the growth of their portfolio companies. In recent years, MIG Capital realized more than ten successful sales, including more recently the portfolio companies Siltectra (to Infineon, 2018) and Hemovent (MicroPort, 2021), and led BRAIN (in 2017), NFON (in 2018), BioNTech (in 2019) and Immatics (in 2020) to listings on stock exchanges. *
![]() |
Start | 2021-11-01 existent |
Group | MIG Fonds (Group) | |
![]() |
Industry | venture capital |
Industry 2 | LIFE SCIENCES | |
![]() |
Person | Motschmann, Michael (MIG Funds 200604) |
Person 2 | Kromayer, Matthias (MIG Funds 201009) | |
![]() |
Region | München (Munich) |
Country | Germany | |
Street | 102 Ismaninger Str. | |
City | 81675 München | |
Address record changed: 2024-01-05 | ||
Basic data | Employees | n. a. |
* Document for »About Section«: Mbiomics GmbH. (3/23/23). "Press Release: Microbiome Therapeutics Biotech Mbiomics Raises EUR 13 Million in First Closing of Series A Round". Munich. | ||
Record changed: 2024-12-29 |
Advertisement

More documents for MIG Fonds (Group)
- [1] Mbiomics GmbH. (3/23/23). "Press Release: Microbiome Therapeutics Biotech Mbiomics Raises EUR 13 Million in First Closing of Series A Round". Munich....
- [2] Temedica GmbH. (11/23/22). "Press Release: Temedica Raises another €25 Million in Series B Funding to Expand Its Unique Real-world Insights Ecosystem". Munich....
- [3] Isarna Therapeutics GmbH. (9/30/21). "Press Release: Isarna Therapeutics Appoints Claus Schalper as CEO". Munich....
- [4] Innatera Nanosystems B.V.. (11/25/20). "Press Release: Innatera Raises €5M to Bring Neuromorphic Intelligence to the Sensor-edge". Delft....
- [5] AdvanceCor GmbH. (6/2/20). "Press Release: AdvanceCor GmbH Closes a further Financing Round with a Consortium of Investors". München/Martinried....
- [6] Temedica GmbH. (1/14/20). "Press Release: Temedica Raises $19 Million Series B Funding". Munich....
- [7] Biocrates Life Sciences AG. (9/12/19). "Press Release: Repositioning of Biocrates – Management Change and New Round of Financing". Innsbruck....
- [8] |transkript [ml, Laqua, Martin]. (6/3/19). "News: Metanomics vor Umbruch"....
To subscribe to our free, monthly newsletter for the European life sciences, please send an e-mail to [email protected] and simply fill the subject line with the word »LSE Newsletter«
Find more infos about advertising at [iito] web portals in our media flyer [iito] in a Nutshell [PDF file]
Advertisement

» top